About fruquintinib
VEGFR tyrosine kinase inhibitor
Used for
- Treats adults with metastatic colorectal cancer after prior standard treatments have stopped working.
Usual adult dose
5 mg by mouth once daily on days 1–21 of each 28-day cycle; continue until progression or unacceptable toxicity.
Common side effects
- High blood pressure
- Tiredness
- Diarrhea
- Hand-foot skin reaction
Important warnings
- Can cause serious bleeding, blood clots, or gastrointestinal perforation.
- Monitor blood pressure and liver tests during treatment.
- May impair wound healing; treatment may need interruption around surgery.
- Avoid live vaccines and report severe or persistent symptoms.
Pregnancy
May harm an unborn baby. Use effective contraception during treatment and for 2 weeks after the final dose.
Breastfeeding
Do not breastfeed during treatment and for 2 weeks after the final dose.
Interactions
- Strong or moderate CYP3A inducers may lower fruquintinib levels; avoid when possible.
- Strong or moderate CYP3A inhibitors may raise levels; monitor for toxicity.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.